Prothena Corporation PLC
NASDAQ:PRTA
Prothena Corporation PLC
Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.
Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.
Clinical Milestones: Prothena expects key clinical readouts in 2025, including topline Phase III results for birtamimab in AL amyloidosis and initial Phase I data for PRX012 in Alzheimer's disease.
Birtamimab Opportunity: Birtamimab could become the first anti-amyloid therapy for AL amyloidosis, targeting early mortality with a potential U.S. launch in the second half of 2026 and multi-billion dollar global sales at peak.
Financials: 2024 financial results were in line with guidance, with net cash used at $150.3 million and net loss at $122.3 million, both at the low end of guided ranges.
2025 Guidance: Prothena projects higher net cash use ($168–175 million) and a year-end cash balance of about $301 million in 2025.
Partnered Programs: Significant progress in partnered programs, including BMS's $80 million license for PRX019 and ongoing trials with Roche and Novo Nordisk, with additional clinical results expected in 2025.
Commercial Preparation: The company is actively preparing for its first commercial launch and building the necessary infrastructure, especially for birtamimab's targeted specialty market.
